Company intelligence / Profile preview

SC MEDICA

Ownership: Private
Development stage: Commercial

Overview

SC MEDICA has developed and commercialized the FFX® system, a minimally invasive spinal implant solution for back pain management and spinal fusion. The system is recognized for its innovation and safety, having won multiple industry awards in 2025. It is protected by five patent families and has received FDA Breakthrough Device Designation. Clinical results highlight immediate and sustainable pain relief with improved patient safety due to radiation-free procedures[1].

Therapeutic areas: OtherRheumatology
Modalities: DeviceImplant
Industry: Implantable Medical Devices

Drug pipeline

1 asset

FFX

Commercial

Indications: Back pain, Lumbar spinal stenosis, Spinal instability

Beyond the preview

Go deeper on SC MEDICA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC MEDICA.

Explore the full profile